Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

This study has been completed.
Information provided by (Responsible Party):
Celgene ( Celgene Corporation ) Identifier:
First received: March 2, 2012
Last updated: August 14, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2014
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)